Terms: = Bone cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Treatment
8 results:
1. Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO
Honecker F; Huschens S; Angermund R; Kallischnigg G; Freier W; Friedrich C; Hartung G; Lutz A; Otremba B; Pientka L; Späth-Schwalbe E; Kolb G; Bokemeyer C; Wedding U;
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3183-3194. PubMed ID: 34312732
[TBL] [Abstract] [Full Text] [Related]
2. SLX4IP acts with SLX4 and xpf-ERCC1 to promote interstrand crosslink repair.
Zhang H; Chen Z; Ye Y; Ye Z; Cao D; Xiong Y; Srivastava M; Feng X; Tang M; Wang C; Tainer JA; Chen J
Nucleic Acids Res; 2019 Nov; 47(19):10181-10201. PubMed ID: 31495888
[TBL] [Abstract] [Full Text] [Related]
3. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract] [Full Text] [Related]
4. Human in vitro skin organ culture as a model system for evaluating DNA repair.
Liu H; Tuchinda P; Fishelevich R; Harberts E; Gaspari AA
J Dermatol Sci; 2014 Jun; 74(3):236-41. PubMed ID: 24636351
[TBL] [Abstract] [Full Text] [Related]
5. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract] [Full Text] [Related]
6. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
Sedda AF; Rossi G; Cipriani C; Carrozzo AM; Donati P
Clin Exp Dermatol; 2008 Nov; 33(6):745-9. PubMed ID: 18681873
[TBL] [Abstract] [Full Text] [Related]
7. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Hasbini A; Mahjoubi R; Fandi A; Chouaki N; Taamma A; Lianes P; Cortès-Funes H; Alonso S; Armand JP; Cvitkovic E; Raymond E
Ann Oncol; 1999 Apr; 10(4):421-5. PubMed ID: 10370784
[TBL] [Abstract] [Full Text] [Related]
8. Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial.
Jäger E; Bernhard H; Klein O; Wächter B; Theiss F; Dippold W; Meyer zum Büschenfelde KH; Knuth A
Ann Oncol; 1995 Feb; 6(2):153-6. PubMed ID: 7540418
[TBL] [Abstract] [Full Text] [Related]
